Literature DB >> 11801993

Remote delivery of rAAV-GFP to the rat brainstem through the recurrent laryngeal nerve.

A D Rubin1, N D Hogikyan, K Sullivan, N Boulis, E L Feldman.   

Abstract

OBJECTIVE: To demonstrate that a recombinant adeno-associated viral vector (rAAV) carrying the gene for green fluorescent protein (GFP) could be delivered to the rat brainstem by remote injection into the recurrent laryngeal nerve. STUDY DESIGN/
METHODS: rAAV-GFP is a serotype 2 adeno-associated vector containing the cDNA of GFP and woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) under the control of the CAG promoter (obtained from Matthew During, PhD, Thomas Jefferson Medical College). Five microliters or 10 microL of 1.4 x 109 particles/microL of rAAV-GFP were injected into the right recurrent laryngeal nerve of adult Sprague-Dawley rats. Rats were killed and perfused at 3 (n = 3) and 11 weeks (n = 3). Brainstems were removed and cryosectioned. Fluorescent in-situ hybridization (FISH) was performed on cryosections from animals killed at 3 weeks using a cDNA probe for woodchuck polyribosomal enzyme within the rAAV vector. In a third group (n = 2), Fluoro-Gold (Fluorochrome, Inc., Denver, CO) was injected into the right thyroarytenoid muscle for comparison of neuronal uptake distribution. These rats were killed and perfused at 3 weeks.
RESULTS: The presence of GFP was noted in neurons throughout the medulla of all rat brainstems after unilateral rAAV-GFP injection at both 3 and 11 weeks. In contrast to the Fluoro-Gold, GFP was noted bilaterally and outside of the nucleus ambiguus. FISH confirmed the presence of virus within neurons expressing GFP at 3 weeks.
CONCLUSIONS: Remote delivery of rAAV-GFP to the rat brainstem is possible through injection into the recurrent laryngeal nerve. This has important therapeutic implications for the future treatment of recurrent laryngeal nerve injury and neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11801993     DOI: 10.1097/00005537-200111000-00032

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

Review 1.  Strategic approaches to developing drug treatments for ALS.

Authors:  Andrea M Vincent; Stacey A Sakowski; Adam Schuyler; Eva L Feldman
Journal:  Drug Discov Today       Date:  2007-11-26       Impact factor: 7.851

2.  Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression.

Authors:  S A Sakowski; S B Heavener; J S Lunn; K Fung; S S Oh; S K Spratt; N D Hogikyan; E L Feldman
Journal:  Gene Ther       Date:  2009-09-03       Impact factor: 5.250

3.  Neuromuscular effects of G93A-SOD1 expression in zebrafish.

Authors:  Stacey A Sakowski; J Simon Lunn; Angela S Busta; Sang Su Oh; Grettel Zamora-Berridi; Madeline Palmer; Andrew A Rosenberg; Stephen G Philip; James J Dowling; Eva L Feldman
Journal:  Mol Neurodegener       Date:  2012-08-31       Impact factor: 14.195

Review 4.  Current Treatment Options for Bilateral Vocal Fold Paralysis: A State-of-the-Art Review.

Authors:  Yike Li; Gaelyn Garrett; David Zealear
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-07-04       Impact factor: 3.372

Review 5.  Gene Therapy for Recurrent Laryngeal Nerve Injury.

Authors:  Koji Araki; Hiroshi Suzuki; Kosuke Uno; Masayuki Tomifuji; Akihiro Shiotani
Journal:  Genes (Basel)       Date:  2018-06-25       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.